- Home
- CFBK vs GALT Comparison
CFBK vs GALT Comparison
Compare CFBK & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFBK | GALT |
|---|---|---|
| Founded | 1892 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.1M | 199.2M |
| IPO Year | 2005 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CFBK | GALT |
|---|---|---|
| Price | $30.11 | $2.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $31.50 | $8.50 |
| AVG Volume (30 Days) | 44.0K | ★ 297.5K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | 30.58 | ★ 36.84 |
| EPS | ★ 0.77 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.99 | N/A |
| Revenue Next Year | $9.09 | N/A |
| P/E Ratio | $38.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.10 | $1.85 |
| 52 Week High | $34.34 | $7.13 |
Technical Indicators
Market Signals| Indicator | CFBK | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 64.21 |
| Support Level | $28.40 | $2.62 |
| Resistance Level | $30.25 | $3.36 |
| Average True Range (ATR) | 0.91 | 0.18 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 54.13 | 85.19 |
Price Performance
Historical ComparisonAbout CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.